| answer text |
<p>As described in the answer of 14 March 2022 to Question 133232, progress towards
the target of halving healthcare-associated Gram-negative bloodstream infections (GNBSI)
has proved very challenging, in part due to the diverse nature of the underlying causes
of these infections. Data on the incidence of these infections in England is published
quarterly by the UK Health Security Agency, and is available at the following link:</p><p><br>
<a href="https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data"
target="_blank">https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data</a></p><p><br>
Incidence of the three main healthcare-associated GNBSI organisms, E. coli, klebsiella
pneumoniae, and pseudomonas aeruginosa, has fluctuated between 2019 and 2024, including
a sharp decline in the incidence of E. coli seen during the COVID-19 pandemic. However,
overall, the total incidence of healthcare associated GNBSI remains significantly
above the target.</p><p>We are currently developing the 2024 to 2029 antimicrobial
resistance national action plan. We anticipate that in the delivery of this plan,
we will continue to focus on GNBSI, building on lessons learnt over the past five
years.</p>
|
|
